Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
14min Summary Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA's RMAT designation and is supported by an Expanded Access Program. Ocugen's broader pipeline includes OCU410 for geographic atrophy and OCU410ST for Stargardt disease, both progressing through early trials. The company faces cash burn challenges but has extended its cash runway to Q3 2025 with a recent $35 million equity raise. I reiterate a “buy” rating on OCGN based on OCU400's promising Phase 3 progress and strong market potential. However, clinical trial risks remain. Jonathan Storey Ocugen Inc. ( NASDAQ: OCGN ) is a clinical-stage biotechnology company developing gene and cell therapies using its proprietary platforms. They aim to restore retinal function in various ocular diseases. Since I last covered OCGN, the company has made promising strides targeting conditions such as retini
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines ConferenceGlobeNewswire
- Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the FirmBusiness Wire
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology WorkshopGlobeNewswire
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders SummitGlobeNewswire
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
OCGN
Earnings
- 8/8/24 - Beat
OCGN
Sec Filings
- 9/26/24 - Form 4
- 8/16/24 - Form 144
- 8/13/24 - Form 8-K
- OCGN's page on the SEC website